Changes in tissue substance P levels in patients with carpal tunnel syndrome

Neurosurgery

Volumn 67, Issue 6, 2010, Pages 1655-1660

  Öztürk, Niyazi ^a   Erin, Nuray ^a   Tüzüner, Serdar ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Carpal tunnel syndrome; Immune; Neuron; Substance P

Indexed keywords

ACETIC ACID; MELOXICAM; SUBSTANCE P;

ADULT; ADVENTITIA; AGED; ARTICLE; CARPAL TUNNEL SYNDROME; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; FIBROSIS; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL; NERVE ENDING; NEUROPATHIC PAIN; PREMEDICATION; PRIORITY JOURNAL; SYNOVIUM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARPAL TUNNEL SYNDROME; CONNECTIVE TISSUE; FEMALE; HUMANS; MALE; MEDIAN NERVE; MIDDLE AGED; MYELIN SHEATH; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUBSTANCE P; TENDONS; THIAZINES; THIAZOLES; YOUNG ADULT;

EID: 78650490994     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3181fa7032     Document Type: Article

References (65)

1. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosen I. Prevalence of carpal tunnel syndrome in a general population. JAMA. 1999;282(2):153-158.
2. Ferry S, Pritchard T, Keenan J, Croft P, Silman AJ. Estimating the prevalence of delayed median nerve conduction in the general population. Br J Rheumatol. 1998;37(6):630-635.
3. Papanicolaou GD, McCabe SJ, Firrell J. The prevalence and characteristics of nerve compression symptoms in the general population. J Hand Surg Am. 2001;26(3):460-466.
4. Graham B, Regehr G, Naglie G, Wright JG. Development and validation of diagnostic criteria for carpal tunnel syndrome. J Hand Surg Am. 2006;31(6):919-924.
5. Manente G, Torrieri F, Pineto F, Uncini A. A relief maneuver in carpal tunnel syndrome. Muscle Nerve. 1999;22(11):1587-1589.
6. Zanette G, Marani S, Tamburin S. Extra-median spread of sensory symptoms in carpal tunnel syndrome suggests the presence of pain-related mechanisms. Pain. 2006;122(3):264-270.
7. Ettema AM, Amadio PC, Zhao C, et al. Changes in the functional structure of the tenosynovium in idiopathic carpal tunnel syndrome: a scanning electron microscope study. Plast Reconstr Surg. 2006;118(6):1413-1422.
8. Faithfull DK, Moir DH, Ireland J. The micropathology of the typical carpal tunnel syndrome. J Hand Surg Br. 1986;11(1):131-132.
9. Kerr CD, Sybert DR, Albarracin NS. An analysis of the flexor synovium in idiopathic carpal tunnel syndrome: report of 625 cases. J Hand Surg Am. 1992;17(6):1028-1030.
10. Ketchum LD. A comparison of flexor tenosynovectomy, open carpal tunnel release, and open carpal tunnel release with flexor tenosynovectomy in the treatment of carpal tunnel syndrome. Plast Reconstr Surg. 2004;113(7):2020-2029.
11. Nakamichi K, Tachibana S. Histology of the transverse carpal ligament and flexor tenosynovium in idiopathic carpal tunnel syndrome. J Hand Surg Am. 1998;23(6):1015-1024.
12. Devor M. Neuropathic pain: what do we do with all these theories Acta Anaesthesiol Scand. 2001;45(9):1121-1127.
13. Gerritsen AA, de Krom MC, Struijs MA, Scholten RJ, de Vet HC, Bouter LM. Conservative treatment options for carpal tunnel syndrome: a systematic review of randomised controlled trials. J Neurol. 2002;249(3):272-280.
14. Dammers JW, Veering MM, Vermeulen M. Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial. BMJ. 1999; 319(7214):884-886.
15. Quartara L, Maggi CA. The tachykinin NK1 receptor, part II: distribution and pathophysiological roles. Neuropeptides. 1998;32(1):1-49.
16. Snijdelaar DG, Dirksen R, Slappendel R, Crul BJ. Substance P.Eur J Pain. 2000;4(2):121-135.
17. Hua XY, Chen P, Marsala M, Yaksh TL. Intrathecal substance P-induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids. Neuroscience. 1999;89(2):525-534.
18. Harrison S, Geppetti P, Substance P. Int J Biochem Cell Biol. 2001;33:555-576.
19. Zieglgansberger W, Berthele A, Tolle TR. Understanding neuropathic pain. CNS Spectr. 2005;10:298-308.
20. Lai X, Wang Z, Wei L, Wang L. Effect of substance P released from peripheral nerve ending on endogenous expression of epidermal growth factor and its receptor in wound healing. Chin J Traumatol. 2002;5(3):176-179.
21. Schubert TE, Weidler C, Lerch K, Hofstadter F, Straub RH. Achilles tendinosis is associated with sprouting of substance P positive nerve fibres. Ann Rheum Dis. 2005;64(7):1083-1086.
22. Walsh DA, Hu DE, Mapp PI, Polak JM, Blake DR, Fan TP. Innervation and neurokinin receptors during angiogenesis in the rat sponge granuloma. Histochem J. 1996;28(11):759-769.
23. Erin N, Ulusoy O. Differentiation of neuronal from non-neuronal substance P. Regul Pept. 2009;152(1-3):108-113.
24. Bianchi M, Broggini M, Balzarini P, Franchi S, Sacerdote P. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract. 2007;61(8):1270-1277.
25. Yamada M, Ogata M, Kawai M, Mashima Y, Nishida T. Substance P and its metabolites in normal human tears. Invest Ophthalmol Vis Sci. 2002;43(8): 2622-2625.
26. Erin N, Ersoy Y, Ercan F, Akici A, Oktay S. NK-1 antagonist CP99994 inhibits stress-induced mast cell degranulation in rats. Clin Exp Dermatol. 2004;29(6): 644-648.
27. Erin N, Clawson GA. Parameters affecting substance P measurement in heart, lung, and skin. Biotechniques. 2004;37(2):232, 234, 236.
28. Padua L, Lo MM, Padua R, Gregori B, Tonali P. Neurophysiological classification of carpal tunnel syndrome: assessment of 600 symptomatic hands. Ital J Neurol Sci. 1997;18(3):145-150.
29. Erin N, Zik B, Sarigul M, Tutuncu S. The effects of chronic low-dose capsaicin treatment on substance P levels. Regul Pept. 2009;153(1-3):83-87.
30. Hislop AA, Wharton J, Allen KM, Polak JM, Haworth SG. Immunohistochemical localization of peptide-containing nerves in human airways: age-related changes. Am J Respir Cell Mol Biol. 1990;3(3):191-198.
31. de Campos CC, Manzano GM, Leopoldino JF, et al. The relationship between symptoms and electrophysiological detected compression of the median nerve at the wrist. Acta Neurol Scand. 2004;110(6):398-402.
32. Cook AJ,Woolf CJ,Wall PD,McMahon SB. Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input. Nature. 1987;325(7000):151-153.
33. Bridges D, Thompson SW, Rice AS. Mechanisms of neuropathic pain. Br J Anaesth. 2001;87:12-26.
34. Le BD. The whole body receptive field of dorsal horn multireceptive neurones. Brain Res Brain Res Rev. 2002;40(1-3):29-44.
35. Sunderland S. Nerves and Nerve Injuries. 2nd ed. Edinburgh, UK: Churchill Livingstone; 1978:672-675.
36. Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. Eur J Pain. 2003;7(4):353-357.
37. Malan TP, Ossipov MH, Gardell LR, et al. Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. Pain. 2000;86(1-2):185-194.
38. Chacur M, Milligan ED, Gazda LS, et al. A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain. 2001;94(3): 231-244.
39. Meert TF, Vissers K, Geenen F, Kontinen VK. Functional role of exogenous administration of substance P in chronic constriction injury model of neuropathic pain in gerbils. Pharmacol Biochem Behav. 2003;76(1):17-25.
40. Carlton SM, Zhou S, Coggeshall RE. Localization and activation of substance P receptors in unmyelinated axons of rat glabrous skin. Brain Res. 1996;734(1-2): 103-108.
41. Nakamura-Craig M, Smith TW. Substance P and peripheral inflammatory hyperalgesia. Pain. 1989;38(1):91-98.
42. Smith PL, Loescher AR, Boissonade FM, Robinson PP. The effect of substance P on the spontaneous discharge from injured inferior alveolar nerve fibres in the ferret. Exp Neurol. 2005;191(2):285-291.
43. De GR, Tazzari PL, Barbara G, Stanghellini V, Corinaldesi R. Detection of substance P immunoreactivity in human peripheral leukocytes. J Neuroimmunol. 1998;82(2):175-181.
44. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol. 1997;159(11):5654-5660.
45. Lai JP, Douglas SD, Zhao M, Ho WZ. Quantification of substance P mRNA in human mononuclear phagocytes and lymphocytes using a mimic-based RT-PCR. J Immunol Methods. 1999;230(1-2):149-157.
46. Lambrecht BN, Germonpre PR, Everaert EG, et al. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol. 1999;29(12):3815-3825.
47. Linnik MD, Moskowitz MA. Identification of immunoreactive substance P in human and other mammalian endothelial cells. Peptides. 1989;10(5): 957-962.
48. Ercan F, Akici A, Ersoy Y, Hurdag C, Erin N. Inhibition of substance P activity prevents stress-induced bladder damage. Regul Pept. 2006;133(1-3):82-89.
49. Amano H, Kurosawa M, Miyachi Y. Possible mechanisms of the concentrationdependent action of substance P to induce histamine release from rat peritoneal mast cells and the effect of extracellular calcium on mast-cell activation. Allergy. 1997;52(2):215-219.
50. Krumins SA, Broomfield CA. C-terminal substance P fragments elicit histamine release from a murine mast cell line. Neuropeptides. 1993;24(1):5-10.
51. Schierhorn K, Brunnee T, Schultz KD, Jahnke V, Kunkel G. Substance-P-induced histamine release from human nasal mucosa in vitro. Int Arch Allergy Immunol. 1995;107(1-3):109-114.
52. Michaelis M, Vogel C, Blenk KH, Arnarson A, Janig W. Inflammatory mediators sensitize acutely axotomized nerve fibers to mechanical stimulation in the rat. J Neurosci. 1998;18(18):7581-7587.
53. Schuind F, Ventura M, Pasteels JL. Idiopathic carpal tunnel syndrome: histologic study of flexor tendon synovium. J Hand Surg Am. 1990;15(3):497-503.
54. Luchetti R, Schoenhuber R, Alfarano M, Deluca S, De CG, Landi A. Serial overnight recordings of intracarpal canal pressure in carpal tunnel syndrome patients with and without wrist splinting. J Hand Surg Br. 1994;19(1):35-37.
55. Ikeda K, Osamura N, Tomita K. Segmental carpal canal pressure in patients with carpal tunnel syndrome. J Hand Surg Am. 2006;31(6):925-929.
56. Bae SJ, Matsunaga Y, Takenaka M, et al. Substance P induced preprotachykinina mRNA, neutral endopeptidase mRNA and substance P in cultured normal fibroblasts. Int Arch Allergy Immunol. 2002;127(4):316-321.
57. Cahill CM, Coderre TJ. Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain. 2002;95(3):277-285.
58. Herzberg U, Murtaugh M, Beitz AJ. Chronic pain and immunity: mononeuropathy alters immune responses in rats. Pain. 1994;59(2):219-225.
59. Herzberg U, Brown DR, Mullett MA, Beitz AJ. Increased delayed type hypersensitivity in rats subjected to unilateral mononeuropathy is mediated by neurokinin- 1 receptors. J Neuroimmunol. 1996;65(2):119-124.
60. Talmor M, Patel MP, Spann MD, et al. COX-2 up-regulation in idiopathic carpal tunnel syndrome. Plast Reconstr Surg. 2003;112(7):1807-1814.
61. Piazzini DB, Aprile I, Ferrara PE, et al. A systematic review of conservative treatment of carpal tunnel syndrome. Clin Rehabil. 2007;21(4):299-314.
62. Taylor-Gjevre RM, Gjevre JA, Strueby L, Boyle CA, Nair B, Sibley JT. Treatments for carpal tunnel syndrome: who does what, when. . .and why Can Fam Physician. 2007;53(7):1186-1190.
63. Lazer ES, Miao CK, Cywin CL, et al. Effect of structural modification of enolcarboxamide- type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem. 1997;40(6):980-989.
64. Gallicchio M, Rosa AC, Benetti E, Collino M, Dianzani C, Fantozzi R. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. Br J Pharmacol. 2006;147(6):681-689.
65. Bergren DR. Prostaglandin involvement in lung C-fiber activation by substance P in guinea pigs. J Appl Physiol. 2006;100(6):1918-1927.